MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Portfolio Companies: Canaan
DexCom, Inc. (NASDAQ: DXCM)
Organization & Developments: Dexcom
Parents
DexCom, Inc. (NASDAQ: DXCM)
Children
*Artificial Pancreas
*Claims to have most accurate sensor on the market and the only sensor approved by the FDA for 7 continuous days of use
*Continuous Glucose Monitoring
*Designs, develops, and commercializes continuous glucose monitoring systems.
*Developments: Dexcom (Archives 2010-2017)
*DexCom has joint development agreements with insulin pump manufacturers Animas Corporation, a subsidiary of Johnson & Johnson, a
*DexCom is the leading CGM (Continuous Glucose Monitor) company
*DexCom’s first generation hospital system recently received CE Mark approval.
*Implantable glucose sensor for diabetics
*It offers 24/7 glucose data and expert coaching designed to help cut cravings, boost energy and lose weight.
*Nutrisense’s offerings enable Dexcom to incorporate access to registered dietitians, personalized nutrition guidance and behavior-change support.
*Only sensor company in the world with commercial approval for a continuous glucose IV sensor intended for the critical care mark
*The company's current commercial offering is the FDA approved SEVEN PLUS system, which also has CE Mark approval for commerciali
2014: Medtronic Diabetes and Dexcom Rivalry To Heat Up
2018: DexCom Continues to Shine Despite Growing Competition in CGM
2018: Dexcom Shows It Can Still Hang With Abbott
2018: Fitbit Ionic Smartwatch to Display Dexcom CGM Data in 2018
2018: VA_65--Dexcom Glucose Sensor 7 and G4 Platinum for VASDHS
2018: VA_65--Emergency Procurement Dexcom Glucose Sensor for Leavenworth Delivery due 02-05-2018 No gray market items accepted
2019: Closed-loop artificial pancreas from Tandem, Dexcom aces Type 1 diabetes study
2019: Dexcom CGM adoption booms as it looks to 'aggressively' pursue Type 2 market
2019: Dexcom Dominates 2018 with Phenomenal Earnings
2019: Dexcom posts 53% US revenue growth in 'blowout' Q3
2019: Dexcom_Why This High-Ranking Medical Stock Can't Seem To Get Traction_www.investors.com
2019: Dexcom: Material Deceleration On The Horizon_seekingalpha.com
2019: IBD Stock Of The Day: Dexcom Nears Breakout On Medical Device Heyday_www.investors.com
2019: Weekend server overload brings down Dexcom's CGM alert feature, raising alarms among parents
2020: Dexcom G6’s applicator issue frustrates patients, caregivers
2020: DexCom: The End Of The Beginning Is Almost Here
2020: DexCom's Preliminary Numbers Shine at J.P. Morgan
2020: JPM20: Livongo strikes deal with Dexcom to integrate continuous glucose monitoring data
2020: What's next for Dexcom? CEO, CTO talk G6 for inpatient use, expanding CGMs for patients without diabetes
2021: Dexcom wins FDA nod for real-time APIs, allowing third-party developers access to CGM data
2021: DexCom: Buy The Dip - Volatility Will Dissipate As Mass Market Opens Up_seekingalpha.com
2021: DexCom's Price: With The New G7 System And Partnerships, It May Spike Up
2022: DexCom: Mid-Term Growth Levers In Place Despite Lofty Multiples_seekingalpha.com
2022: DexCom: Still Too Expensive_seekingalpha.com
2023: ADA: Dexcom plots 2024 launch of sensor for people with Type 2 diabetes who don't use insulin
2023: Dexcom sets new user records in first quarter following G7 kickoff
2023: Up 60%, Why I Believe DexCom Is One Of The Best Healthcare Stocks Money Can Buy_ seekingalpha.com
2024: DexCom Growing Into Its Valuation, But Still No Bargain
2024: DexCom Is Pricey For A Reason - Its Growth Story Reflects That
2024: Dexcom over-the-counter Stelo Glucose Biosensor wins FDA clearance
2024: Dexcom Pares Steep Losses Despite A Key Exec Departure Amid Stelo Launch
2024: DexCom Q2 Earnings: Traditional Market Overreaction
2024: Dexcom receives FDA clearance for first OTC glucose sensor
2024: Dexcom shares plunge after it cuts annual revenue forecast
2024: DexCom: A Wealth Compounder In Healthcare
2024: DexCom: Exiting The 'Expansion Phase' As Competition Intensifies
2024: DexCom's Competitive Landscape: A Deep Dive Into The CGM Market
2024: Smart ring maker Oura picks up $75M series D, inks strategic partnership with Dexcom
2024: Watch These Dexcom Price Levels as Stock Plunges After Guidance Slashed
2024: Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
2024:Dexcom Stelo hands-on: an OTC gadget in the war against diabetes
2025: Dexcom CEO talks Stelo sensor launch, OTC strategy
2025: Dexcom execs say company has fixed G7 quality problems
2025: DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
2025:DexCom Stock Drops as Diabetes Devices Maker Gets FDA Warning Letter
2026: Q&A: Jake Leach on expanding Dexcom CGM access, wearables and AI
Jumps
*Key People: Dexcom
Finance & Acquisitions: Dexcom